Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single-dose intravenous NI-0801 safety study in healthy volunteers
NL-OMON33532Phase 1Active, not recruiting
- Sponsor
- Lightchain Bioscience
- Start
- Aug 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in psoriasis comparing NI-0801 with Placebo (2 arms). Primary endpoint: Safety and tolerability of escalating single IV doses of NI-0801. Started Aug 2008; status: active, not recruiting.
02
Drugs
NI-0801
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON33532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33532.